



Universiteit
Leiden

The Netherlands

Colorectal cancer screening for average- and high-risk individuals: beyond one-size-fits-all

Breekveldt, E.C.H.

Citation

Breekveldt, E. C. H. (2024, June 5). *Colorectal cancer screening for average- and high-risk individuals: beyond one-size-fits-all*.

Retrieved from <https://hdl.handle.net/1887/3759760>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3759760>

Note: To cite this publication please use the final published version (if applicable).

COLORECTAL CANCER SCREENING FOR AVERAGE- AND HIGH-RISK INDIVIDUALS

Beyond one-size-fits-all

1. Monitoring and evaluation made it possible to demonstrate the positive effects of the Dutch colorectal cancer screening program on long-term parameters, such as a stage distribution shift and reduced (late-stage) colorectal cancer incidence; future regulations should ensure this is maintained (*this thesis*).
2. Fecal hemoglobin concentrations should be used to risk stratify colorectal cancer screening programs for average- and high-risk individuals (*this thesis*).
3. Considering the favorable outcomes of the Dutch colorectal cancer screening program, maintaining engagement of the target population is vital (*this thesis*).
4. Determining if and how cisplatin leaves a signature in the colorectal mucosa that leads to colorectal cancer carcinogenesis in testicular cancer survivors will be the key for providing surveillance guidelines for these high-risk individuals (*this thesis*).
5. Non-invasive tests for both average and high-risk populations may be appropriately compared to fecal immunochemical testing rather than the gold standard of colonoscopy (*Bresalier et al, Gut, 2023*).
6. Randomized controlled trials have inherent limitations and biases due to complex processes, such as patient selection, blinding, and treatment implementation, necessitating exploration of alternative methods to evaluate the effectiveness of new screening strategies (*Krauss et al, Annals of Medicine, 2018*).
7. Pan-cancer genome analysis reveals key mutational insights for innovative screening and treatment, but challenges in cancer heterogeneity and ethics impede evidence-based implementation (*The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Nature, 2020*).
8. The global medical community, too, should work together to minimize the (healthcare) risks of climate change as soon as possible (*Romanello et al, Lancet, 2023*).
9. *One can be kind but strong, empathetic but decisive, optimistic but focused – you can be your own kind of leader* -vrije vertaling Jacinda Arden – Wilskracht, gedrevenheid en empathie in persoonlijk leiderschap kunnen wel degelijk naast elkaar bestaan.
10. *Gut feelings are proverbially better guides to the truth than overthought, conscious judgments* -John-Michael Kuczynski – Het maken van keuzes op gevoel heeft me gebracht tot waar en wie ik ben.
11. *We borduren maar wat voort op het gouden koord* - Emmy en Jacqueline Anker - Feedback is a gift.